Research Paper Volume 15, Issue 12 pp 5650—5661
Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma
Figure 5. Enrichment analysis of the immune prognostic model. (A) Correlation of the risk score with the expression of several prominent immune checkpoint molecules. (B) Violin plots illustrating immune checkpoint molecules at significant levels between high-risk and low-risk patients.